Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1

ABSTRACT The human immunodeficiency virus envelope glycoproteins function as trimers on the viral surface, where they are targeted by neutralizing antibodies. Different monoclonal antibodies neutralize human immunodeficiency virus type 1 (HIV-1) infectivity by binding to structurally and functionally distinct moieties on the envelope glycoprotein trimer. By measuring antibody neutralization of viruses with mixtures of neutralization-sensitive and neutralization-resistant envelope glycoproteins, we demonstrate that the HIV-1 envelope glycoprotein trimer is inactivated by the binding of a single antibody molecule. Virus neutralization requires essentially all of the functional trimers to be occupied by at least one antibody. This model applies to antibodies differing in neutralizing potency and to virus isolates with various neutralization sensitivities. Understanding these requirements for HIV-1 neutralization by antibodies will assist in establishing goals for an effective AIDS vaccine.

[1]  J. Hoxie,et al.  The Stoichiometry of Trimeric SIV Glycoprotein Interaction with CD4 Differs from That of Anti-envelope Antibody Fab Fragments* , 2001, The Journal of Biological Chemistry.

[2]  S. Zolla-Pazner,et al.  Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. , 1997, Journal of immunology.

[3]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[4]  J. Skehel,et al.  Mechanism of neutralization of influenza virus infectivity by antibodies. , 2002, Virology.

[5]  A. Trkola,et al.  HIV type 1 coreceptors, neutralization serotypes, and vaccine development. , 1997, AIDS research and human retroviruses.

[6]  E. Fenyö,et al.  Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. , 1997, Virology.

[7]  J. Sodroski,et al.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.

[8]  A. Ishimoto,et al.  Analysis of dominant-negative effects of mutant Env proteins of human immunodeficiency virus type 1. , 2001, Virology.

[9]  J. L. Raina,et al.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. , 1992, Virology.

[10]  Abraham Pinter,et al.  Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.

[11]  K. Reimann,et al.  Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses. , 1999, Virology.

[12]  S. Durell,et al.  Dilation of the influenza hemagglutinin fusion pore revealed by the kinetics of individual cell-cell fusion events , 1996, The Journal of cell biology.

[13]  J. Bonifacino,et al.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[15]  Gilcher Ro.  Human retroviruses and AIDS. , 1988 .

[16]  W. Koff,et al.  AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. , 2004, Science.

[17]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[18]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[19]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[20]  P. Earl,et al.  Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein , 1991, Journal of virology.

[21]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[22]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[23]  Q. Sattentau,et al.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4. , 1990, Science.

[24]  T. Brubaker,et al.  Nonlinear Parameter Estimation , 1979 .

[25]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[26]  K. Salzwedel,et al.  Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Kenneth A. Taylor,et al.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Sodroski,et al.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. , 2000, AIDS research and human retroviruses.

[29]  J. Moore,et al.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies , 1994, Journal of virology.

[30]  P. Bugelski,et al.  Morphometric analysis of envelope glycoprotein gp120 distribution on HIV-1 virions. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  T. Copeland,et al.  Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. , 1986, The Journal of general virology.

[32]  J. Sodroski,et al.  Characterization of Primary Isolate-Like Variants of Simian-Human Immunodeficiency Virus , 1999, Journal of Virology.

[33]  I. Jones,et al.  Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin , 1993, Journal of virology.

[34]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[35]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[36]  Robyn L Stanfield,et al.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. , 2004, Structure.

[37]  J. Robinson,et al.  Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Hoxie,et al.  Envelope Glycoprotein Incorporation, Not Shedding of Surface Envelope Glycoprotein (gp120/SU), Is the Primary Determinant of SU Content of Purified Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 2002, Journal of Virology.

[39]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[40]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[41]  A. Trkola,et al.  Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[42]  D R Burton,et al.  A model for neutralization of viruses based on antibody coating of the virion surface. , 2001, Current topics in microbiology and immunology.

[43]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[44]  J. Sodroski,et al.  Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus , 2000, Journal of Virology.

[45]  S. Pelletier,et al.  Membrane fusion mediated by the influenza virus hemagglutinin requires the concerted action of at least three hemagglutinin trimers , 1996, The Journal of cell biology.

[46]  N J Dimmock,et al.  Competitive binding of neutralizing monoclonal and polyclonal IgG to the HA of influenza A virions in solution: only one IgG molecule is bound per HA trimer regardless of the specificity of the competitor. , 1994, Virology.

[47]  J. Robinson,et al.  Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. , 1990, AIDS research and human retroviruses.

[48]  H. Fleury,et al.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals , 1997, Journal of virology.

[49]  R. Doms,et al.  Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity , 2004, Journal of Virology.

[50]  N. Dimmock,et al.  Quantitative relationships between an influenza virus and neutralizing antibody. , 1987, Virology.

[51]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[52]  L. Cavacini,et al.  Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. , 1993, Journal of acquired immune deficiency syndromes.

[53]  G. Pauli,et al.  The organization of the envelope projections on the surface of HIV , 2005, Archives of Virology.

[54]  R. Webster,et al.  Posttranslational oligomerization and cooperative acid activation of mixed influenza hemagglutinin trimers , 1988, The Journal of cell biology.

[55]  Yonathan Bard,et al.  Nonlinear parameter estimation , 1974 .

[56]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[57]  John P. Moore,et al.  Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site , 2003, Journal of Virology.

[58]  Peter D. Kwong,et al.  The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.

[59]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[60]  D. Kabat,et al.  Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[61]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[62]  J. Sodroski,et al.  Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers , 2001, Journal of Virology.

[63]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[64]  N. G. Wrigley.  Electron microscopy of influenza virus. , 1979, British medical bulletin.

[65]  G. Pauli,et al.  Determination of the size of HIV using adenovirus type 2 as an internal length marker. , 1994, Journal of virological methods.

[66]  N. Dimmock,et al.  Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. , 1994, The Journal of general virology.

[67]  D. Birx,et al.  Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. , 1995, AIDS research and human retroviruses.

[68]  J. Sodroski,et al.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.

[69]  Q. Sattentau,et al.  Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation , 1996, The Journal of experimental medicine.

[70]  K. Schønning,et al.  Stoichiometry of Monoclonal Antibody Neutralization of T-Cell Line-Adapted Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.

[71]  G. Shaw,et al.  Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions , 1987, Journal of virology.

[72]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[73]  S. Zolla-Pazner,et al.  Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 , 2001, Journal of Virology.

[74]  J. Sodroski,et al.  Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. , 2003, AIDS research and human retroviruses.

[75]  C. Barbas,et al.  Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies , 1998, Journal of Virology.

[76]  P. Earl,et al.  Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates , 1996, Journal of virology.

[77]  S. Zolla-Pazner,et al.  Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage , 1998, Journal of Virology.

[78]  H. Katinger,et al.  Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies , 2001, Journal of Virology.

[79]  J. Bentz,et al.  Minimal aggregate size and minimal fusion unit for the first fusion pore of influenza hemagglutinin-mediated membrane fusion. , 2000, Biophysical journal.

[80]  N. Kaverin,et al.  Formation of mixed hemagglutinin trimers in the course of double infection with influenza viruses belonging to different subtypes. , 1988, Virus research.

[81]  A. Bourinbaiar,et al.  The ratio of defective HIV-1 particles to replication-competent infectious virions. , 1994, Acta virologica.

[82]  G. Melikyan,et al.  The fusion kinetics of influenza hemagglutinin expressing cells to planar bilayer membranes is affected by HA density and host cell surface , 1995, The Journal of general physiology.

[83]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[84]  J. Moore,et al.  Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement , 1996, Journal of virology.

[85]  J. Sodroski,et al.  Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys , 1997, Journal of virology.

[86]  W. Koff,et al.  Developing an AIDS Vaccine: Need, Uncertainty, Hope , 2004, Science.

[87]  T. Stegmann,et al.  Membrane Fusion Mechanisms: The Influenza Hemagglutinin Paradigm and its Implications for Intracellular Fusion , 2000, Traffic.